- Home
- IMA vs TENX Comparison
IMA vs TENX Comparison
Compare IMA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | TENX |
|---|---|---|
| Founded | 2019 | 1967 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 56.2M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | IMA | TENX |
|---|---|---|
| Price | $6.04 | $12.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $16.00 | ★ $29.67 |
| AVG Volume (30 Days) | 369.6K | ★ 556.0K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.94 | $5.34 |
| 52 Week High | $17.50 | $18.38 |
Technical Indicators
Market Signals| Indicator | IMA | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 38.83 |
| Support Level | $5.52 | $10.83 |
| Resistance Level | $7.17 | $14.15 |
| Average True Range (ATR) | 0.36 | 1.01 |
| MACD | 0.03 | -0.24 |
| Stochastic Oscillator | 77.12 | 0.27 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.